BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17825518)

  • 1. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
    Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
    Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
    van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
    Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI).
    Rossi CR; De Salvo GL; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Montesco MC; Casara D; Schiavon M; Foletto M; Baldini F; Testori A
    J Nucl Med; 2006 Feb; 47(2):234-41. PubMed ID: 16455628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
    de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognosis after sentinel node biopsy in malignant melanoma].
    Lock-Andersen J; Horn J; Sjøstrand H
    Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.
    Yee VS; Thompson JF; McKinnon JG; Scolyer RA; Li LX; McCarthy WH; O'Brien CJ; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Uren RF
    Ann Surg Oncol; 2005 Jun; 12(6):429-39. PubMed ID: 15886905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
    Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
    Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel node identification by scintigraphic methods in cutaneous melanoma.
    Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM
    J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.
    Gipponi M; Di Somma C; Peressini A; Solari N; Gliori S; Nicolo G; Schenone F; Queirolo P; Sertoli MR; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):133-40. PubMed ID: 14991885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
    Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
    Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma.
    Lee JH; Essner R; Torisu-Itakura H; Wanek L; Wang H; Morton DL
    J Clin Oncol; 2004 Sep; 22(18):3677-84. PubMed ID: 15365064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.
    van der Ploeg AP; van Akkooi AC; Schmitz PI; Koljenovic S; Verhoef C; Eggermont AM
    Eur J Cancer; 2010 Sep; 46(13):2414-21. PubMed ID: 20621467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.